To clarify whether vitamin-K prophylaxis in newborns is effective, a double-blind study with oral vitamin-K2 syrup was performed. There were no side-effects. Various dosages of vitamin K2 or placebo syrup were tried in 148 newborns with thrombotest results below 20%. The efficiency decreased as follows: vit-K2 6 mg greater than vit-K2 2 mg greater than vit-K1 2 mg greater than placebo. The effect of all vitamin K preparations on the coagulation system was significantly different from the placebo effect. With regard to our own results and the literature, general vitamin-K prophylaxis for newborns is not recommended. However, vitamin K 1 X 6 mg orally is helpful in newborns with thrombotest results below 20%, in infants at risk, and in all premature, dystrophic or otherwise underweight infants.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Direct factor Xa inhibitors versus low molecular weight heparins or vitamin K antagonists for prevention of venous thromboembolism in elective primary hip or knee replacement or hip fracture repair.
Cochrane Database Syst Rev
January 2025
Division of Pulmonary, Critical Care, Sleep, and Occupational Medicine, Indiana University School of Medicine, Indianapolis, USA.
Background: People undergoing major orthopaedic surgery are at increased risk of postoperative thromboembolic events. Low molecular weight heparins (LMWHs) are recommended for thromboprophylaxis in this population. New oral anticoagulants, including direct factor Xa inhibitors, are recommended as alternatives.
View Article and Find Full Text PDFSecondary Prevention of Stroke in Patients with Non-Valvular Atrial Fibrillation and Advanced Chronic Kidney Disease.
J Atheroscler Thromb
January 2025
Department of Cardiology, the First Affiliated Hospital of Dalian Medical University.
Aims: Evidence supporting the prescription of anticoagulant therapy for patients with atrial fibrillation (AF) with advanced chronic kidney disease (CKD) has been limited, and its clinical application in this context remains controversial.
Methods: We identified AF patients with advanced CKD (G4-G5) and a history of stroke who were admitted to the First Affiliated Hospital of Dalian Medical University between January 1, 2011, and June 30, 2023. Patients were classified into warfarin, non-vitamin K antagonist oral anticoagulant (NOAC), antiplatelet therapy, and control (no antithrombotic therapy) groups.
Unusual Manifestation of Vitamin K Deficiency, Nodular Purpura: A Case Series.
Indian Dermatol Online J
December 2024
Department of Dermatology, St John's Medical College, Bangalore, Karnataka, India.
Vitamin K deficiency is a common entity in infancy characterized by bleeding from various sites, intracranial bleeding being the most commonly reported feature. Nodular purpura is an uncommon manifestation of vitamin K deficiency in infancy with a few reported cases in literature. We present four cases of infants presenting with nodular purpura as a manifestation of late-onset vitamin K deficiency bleeding (VKDB).
View Article and Find Full Text PDFSuppressive effect of vitamin K (menatetrenone) against bone mineral density loss after radiotherapy in uterine cancer patients.
Jpn J Radiol
January 2025
Department of Obstetrics and Gynecology, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan.
Purpose: This study aimed to investigate whether vitamin K (menatetrenone) suppresses bone mineral density (BMD) loss in the irradiated region after radiotherapy (RT) in uterine cancer patients.
Materials And Methods: Our study included 34 patients who underwent whole pelvic irradiation for uterine cancer between 2001 and 2010. The patients were categorized in two groups: (1) Vitamin K (45 mg/day) administration group (group A) with 18 cases and (2) non-administered group (group B) with 16 cases.
Comparative safety and effectiveness of oral anticoagulants in key subgroups of patients with non-valvular atrial fibrillation and at high risk of gastrointestinal bleeding: A cohort study based on the French National Health Data System (SNDS).
PLoS One
January 2025
Pfizer Ltd., Tadworth, United Kingdom.
Background: Risk factors and comorbidities can complicate management of non-valvular atrial fibrillation. We describe and compare real-world safety and effectiveness of direct oral anticoagulants (DOACs; apixaban, rivaroxaban, dabigatran) and vitamin K antagonists (VKAs) in subgroups of patients with non-valvular atrial fibrillation at high risk for gastrointestinal (GI) bleeding, utilizing data from a national quasi-exhaustive French database.
Methods: Anticoagulant-naïve adults with non-valvular atrial fibrillation with ≥1 gastrointestinal bleeding risk factor, initiating anticoagulant treatment January 2016-December 2019, and covered by the French national health data system were eligible.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!